A comparison of treatment strategies for hypoplastic left heart syndrome using decision analysis  by Jenkins, Pamela C et al.
Pediatric Cardiology
A Comparison of Treatment
Strategies for Hypoplastic
Left Heart Syndrome Using Decision Analysis
Pamela C. Jenkins, MD, PHD,* Michael F. Flanagan, MD, FACC,* James D. Sargent, MD,*
Charles E. Canter, MD, FACC,† Richard E. Chinnock, MD,‡ Kathy J. Jenkins, MD, MPH,§
Robert N. Vincent, MD, FACC,\ Gerald T. O’Connor, PHD, DSC, FACC,¶ Anna N. A. Tosteson, SCD¶
Hanover, New Hampshire; St. Louis, Missouri; Loma Linda, California; Boston, Massachusetts;
and Atlanta, Georgia
OBJECTIVES We sought to identify the optimal treatment strategy for hypoplastic left heart syndrome
(HLHS).
BACKGROUND Surgical treatment of HLHS involves either transplantation (Tx) or staged palliation of the
native heart. Identifying the best treatment for HLHS requires integrating individual patient
risk factors and center-specific data.
METHODS Decision analysis is a modeling technique used to compare six strategies: staged surgery; Tx;
stage 1 surgery as an interim to Tx; and listing for transplant for one, two, or three months
before performing staged surgery if a donor is unavailable. Probabilities were derived from
current literature and a dataset of 231 patients with HLHS born between 1989 and 1994. The
goal was to maximize first-year survival.
RESULTS If a donor is available within one month, Tx is the optimal choice, given baseline probabilities;
if no donor is found by the end of one month, stage 1 surgery should be performed. When
survival and organ donation probabilities were varied, staged surgery was the optimal choice
for centers with organ donation rates ,10% in three months and with stage 1 mortality
,20%. Waiting one month on the transplant list optimized survival when the three-month
organ donation rate was $30%. Performing stage 1 surgery before listing, or performing stage
1 surgery after an unsuccessful two- or three-month wait for transplant, were almost never
optimal choices.
CONCLUSIONS The best strategy for centers that treat patients with HLHS should be guided by local organ
availability, stage 1 surgical mortality and patient risk factors. (J Am Coll Cardiol 2001;38:
1181–7) © 2001 by the American College of Cardiology
Parents and caregivers of children with hypoplastic left heart
syndrome (HLHS) are faced with difficult choices from the
moment the diagnosis is made. Some physicians may
recommend comfort care (1), but most will recommend
surgical treatment of the defect. Although studies have
shown transplantation (Tx) to have better one- and five-year
survival than staged surgery (2,3), heart donors are difficult
to find. Infants with HLHS could wait six months or more
on the transplant list, with longer waiting time generating
an increased risk of death on the waiting list, removal from
the list for organ failure and possibly increased risk of death
even after a successful Tx (4–6). If the infant never receives
a donor heart and a stage 1 procedure is performed after a
wait, the child may have an increased mortality risk after
stage 1 surgery attributable to the wait (5,7,8). Identifying
the best treatment strategy for a child with HLHS requires
integrating individual risk factors with center-specific data.
The wide variation in decision making among caregivers of
these children reveals how daunting this task is.
Decision analysis provides a framework for quantitatively
identifying the treatment strategy that, on average, has the
highest chance of success (9,10). Decision analysis is a
modeling technique that structures the problem into
choices, chance events and outcome measures. It is espe-
cially useful for comparing strategies that are not in current
practice with those that are well established (11). Further-
more, by showing how changes in probabilities influence the
optimal treatment strategy, decision analysis helps focus
attention on which probabilities are important to the deci-
sion.
The techniques of decision analysis were used to compare
surgical options for the treatment of HLHS so as to
maximize one-year survival. The goal was to identify
whether one treatment strategy optimized survival in all
cases, or whether the optimal strategy changed depending
on characteristics of patients or centers. The analysis used
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data from the literature and from values obtained in a
dataset of 231 patients with HLHS treated at four surgical
centers between 1989 and 1994 (3).
METHODS
Clinical strategies/decision tree. Treatment strategies
that are well established were compared with new possibil-
ities for treatment (Table 1). The options were to complete
staged surgery; to use stage 1 surgery as an interim proce-
dure to Tx; to list the patient for Tx and perform staged
surgery if no donor is found in a specified time; and to wait
for a donor heart without recourse to staged surgery (Fig. 1).
Strategies known to create lower survival for most babies
with HLHS, such as not performing stage 2 surgery after a
stage 1 procedure (12,13), were not included. The software
used was DATA 3.0 (TreeAge Software, Inc., Williamstown,
Massachusetts).
Outcome. We sought to maximize survival at one year.
Infants with HLHS who survive the first year are highly
likely to survive five years (2,3).
Probabilities. When possible, baseline probabilities and
sensitivity analysis ranges (Table 2) were obtained from
literature reports of patients with HLHS born after 1989
(2,3,7,12,14–23). When no current information was avail-
able, probabilities were obtained from older publications
detailing HLHS treatment (5,24), from the general pediat-
ric transplant literature (25–27), or from a dataset of 231
patients with HLHS born between 1989 and 1994, whose
major survival results have been published (3). Decision-tree
values were assigned using the most recent information with
the largest number of cases reported. Where appropriate,
published survival data were recalculated to yield intention-
to-treat data, comparable across studies. For example, one
report (5) cited the pretransplant mortality for patients with
HLHS as 19%; including patients who were unlisted
increased the waiting-list mortality to 25%. Another report
(23) calculated stage 1 survival as 86%; for purposes of
comparability, including patients older than one month at
surgery lowered stage 1 survival to 83%.
Directly related probabilities were linked in the tree by
assigning multiples of the original probability to the related
probability. For example, the probability of receiving a
donor increased over the first three months of waiting, then
leveled off (Fig. 2) in our dataset. The assigned values of this
probability at two (0.58) and three (0.68) months were
fractional multiples of the one-month value (0.38).
Assumptions. Infants with HLHS were assumed to be
eligible for any surgical strategy on the decision tree. Once
infants entered a treatment strategy, they stayed in that
strategy. Probabilities obtained from the HLHS dataset and
from literature reviews were assumed to be representative of
outcomes for HLHS surgical treatment. Stage 1 mortality
encompassed all deaths between the first operation and the
second operation. Waiting on the transplant list was as-
sumed to affect only mortality after a subsequent stage 1
surgery, and not stage 2 mortality. In our dataset all patients
in the Tx strategy either received a transplant or died by six
months of age; thus, probabilities of waiting indefinitely
until transplant were equated with values for a six-month
wait.
Sensitivity analysis. Sensitivity analysis is a method of
varying probabilities over a defined range to determine how
the optimal choice would change if the value of a chance
event changed. Sensitivity analysis can be performed on
individual probabilities (one-way sensitivity analysis) or
performed by varying two probabilities at the same time
(two-way sensitivity analysis). One-way sensitivity analysis
was performed for each probability in the decision tree, and
the values at which the optimal strategy changed (threshold
values) were identified. Two-way sensitivity analyses were
performed for all probabilities.
RESULTS
The comparison of treatment strategies for HLHS in
Figure 1 showed that performing Tx within one month, and
Abbreviations and Acronyms
HLHS 5 hypoplastic left heart syndrome
Tx 5 transplantation
Table 1. Treatment Strategies for Hypoplastic Left Heart Syndrome Considered at Diagnosis
Name Description of Strategy
Staged surgery Stage 1 and stage 2 surgeries are performed.
Stage 1, then list Stage 1 is performed and the patient is listed for transplantation.
Patient receives a transplant if an organ is available.
List, wait 1 month If an organ is found within one month, the patient receives a
transplant. If no organ is found in that time, Stage 1 is
performed, followed by stage 2.
List, wait 2 months If an organ is found within two months, the patient receives a
transplant. If no organ is found in that time, Stage 1 is
performed, followed by stage 2.
List, wait 3 months If an organ is found within three months, the patient receives a
transplant. If no organ is found in that time, Stage 1 is
performed, followed by stage 2.
List, wait until transplant Patient waits indefinitely until an organ is available.
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then if no donor is found performing staged surgery, proved
the optimal choice for survival at one year, given the
parameters in Table 2. The expected one-year survival of
“list 1 month” was 59%, slightly higher than the expected
survival for “list 2 months” and “list 3 months” of 56%, and
for “list until Tx” of 58%. For “staged surgery,” expected
one-year survival was 49%; and for “stage 1 then list,”
expected survival was 32%.
One-way sensitivity analyses were performed on each
probability to allow it to vary across a range. These sensi-
tivity analyses (Fig. 3) revealed probability thresholds at
which the optimal choice changed from one strategy to
another. Factors whose values changed the optimal treat-
ment strategy were stage 1 mortality, stage 2 mortality, the
three-month organ donation rate and mortality after Tx. By
one-way analysis, a center that finds 80% of its listed infants
with HLHS a donor organ in three months will have the
best survival outcomes by waiting indefinitely for a donor,
whereas a center with a three-month organ donation rate
,8% would have the highest survival by offering staged
surgery at the outset.
In two-way sensitivity analyses, staged surgery, listing for
one month before performing stage 1 surgery, and listing
indefinitely until Tx were the strategies that generated the
highest survival in almost all analyses. The strategy of
performing stage 1 surgery as an interim procedure to Tx
never generated a higher survival than the other strategies.
Waiting two or three months for Tx before performing
stage 1 surgery also had worse one-year survival in almost all
scenarios, due to the designation of rapidly rising mortality
after these waits and stage 1 surgery (Table 2). The two-way
sensitivity analysis varying organ availability and combined
stage 1 mortality is presented in Figure 4; these two
probabilities were the most important ones in the decision
tree. For organ availability ,10% in three months, or for a
combined stage 1 mortality of ,20%, staged surgery was the
best option. For organ availability .30% to 40% in three
months, listing the infant for Tx for at least one month
optimized survival. If stage 1 mortality and the three-month
organ donation rates were both 30%, values lying on a
dividing line between strategies, the staged surgical strategy
and the strategy of listing for one month generated equiv-
alent survival outcomes.
DISCUSSION
This study combined relevant information in a structured
way to improve decision making for the surgical manage-
Figure 1. The decision tree comparing surgical treatment strategies for hypoplastic left heart syndrome (HLHS) is shown. Once HLHS is diagnosed, a
decision (open square) is made as to which treatment strategy to undertake. After the strategy is decided, events (open circles) occur, with defined
probabilities for mutually exclusive outcomes, “survive” or “die.” Survival to surgery or to listing for transplantation (Tx) is not certain, and a probability
is associated with that survival. All babies surviving to surgery are assumed to receive that treatment as planned. The outcome measure was survival to one
year.
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ment of hypoplastic left heart syndrome. In this decision
analysis, under baseline probabilities, the best treatment
strategy for patients with HLHS involved performing Tx
within one month, and then if no donor is found perform-
ing staged surgery. To optimize survival outcomes while
accounting for the trade-off between organ availability and
stage 1 mortality rates, we varied these probabilities at the
same time in a two-way sensitivity analysis. Figure 4 is
essentially a decision-making algorithm using these two
probabilities to determine the optimal strategy. It showed
that for low organ availability (,10% in three months) or
for a low combined stage 1 mortality (,20%), staged
surgery was the best option. For a center with moderate
organ availability (.30% to 40% in three months), listing
the infant for Tx for at least one month optimized survival.
The strategies with less favorable survival were those of
performing staged surgery after an unsuccessful two- to
three-month wait for a donor and of performing stage 1
surgery and then listing the patient for Tx.
A center’s specific organ donation pattern and survival
outcomes can inform the surgical decision, as above, to
optimize survival for an “average” patient with HLHS.
Patient-specific risk factors for mortality and organ avail-
ability are also highly applicable to this decision analysis.
Although many preoperative characteristics of patients with
HLHS have been implicated as increasing mortality risk—
for staged surgery: size of the descending or ascending aorta;
aortic and mitral atresia, obstruction to pulmonary venous
return, noncardiac congenital anomalies, age .1 month at
surgery, lower birth weight, high creatinine and acidosis
(2,3,8,20,21,23,28); for Tx: previous sternotomy, noniden-
tical blood type, specific recipient blood types, high creati-
nine, restrictive atrial septal defect and lower birth weight
(3,26,29)—none have been consistent risk factors for mor-
tality across all studies. When consensus is reached on risk
factors for mortality in HLHS, this information can be used
with Figure 4 to determine the strategy with the highest
expected survival for an individual patient. For instance, if
one infant with HLHS had an expected stage 1 mortality
of 20% at a center with moderate donor availability,
staged surgery would optimize that infant’s survival.
Figure 2. The probabilities of receiving a transplant and of waiting-list
mortality, depicted on the vertical axis, are shown as a function of age in
days on the horizontal axis. Both probabilities increase with time on the
waiting list. Data are derived from the hypoplastic left heart syndrome
dataset (3).
Table 2. Probabilities Used in the Decision Tree
Probability
Decision







Mortality before stage 1 0.01 Jacobs, 1998 253 0.02–0.04 (3,23) 0–0.30
Combined stage 1 mortality 0.48 Jacobs, 1998 250 0.17–0.50 (2,3,7,14,15,18–22) 0–0.80
For 1-month wait 0.50 Jenkins, 2000 7 0.50 (2)
For 2-month wait 0.71 Iannettoni, 1994 7
For 3-month wait 0.85 *
Stage 2 mortality 0.04 Williams, 2000 106 0.00–0.17 (2,3,12,17–20) 0–0.50
Finding a donor after stage 1 surgery 0.75 Bove, 1991 4 0.75–1.00 0–1.00
Mortality after stage 1 and transplant 0.17 Jenkins, 2000 4 0–0.67 (21,24,26) 0–1.00
Organ donation in 1 month 0.38 Jenkins, 2000 112 0.23–0.53 (2,5,25)
In 2 months 0.58 Jenkins, 2000 112 0.46–0.77 (2,25)
In 3 months 0.64 Jenkins, 2000 112 0.67–0.80 (2,25) 0–0.90
In indefinite wait 0.70 Jenkins, 2000 112 0.45–0.96 (2,5,21,25)
Transplant mortality for 1-month wait 0.17 Jenkins, 2000 44 0–0.17 (5,25)
For 2-month wait 0.17 Jenkins, 2000 67 0–0.22 (5,25)
For 3-month wait 0.17 Jenkins, 2000 72 0–0.29 (5,25) 0–0.75
For indefinite wait 0.17 Jenkins, 2000 78 0–0.43 (5,25–27)
Waiting list mortality in 1 month 0.04 Jenkins, 2000 112 0.02–0.10 (2,25)
In 2 months 0.14 Jenkins, 2000 112 0.04–0.16 (2,25)
In 3 months 0.17 Jenkins, 2000 112 0.04–0.18 (2,25) 0–0.50
In indefinite wait 0.29 Jenkins, 2000 112 0.04–0.55 (2,5,25)
*No data were available for this probability; it was assigned based on related published values.
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However, if another infant with HLHS had an expected
stage 1 mortality of 80%, and the center had moderate
donor availability, listing the infant for one month before
proceeding to staged surgery would optimize the infant’s
survival.
Study limitations. A possible limitation of using current
literature values is that the reports may reflect only best
practice or may not be representative of smaller-volume
centers. However, varying the probabilities across a wide
range in sensitivity analyses allows the results to be gener-
alizable over time and across centers. In essence, unpub-
lished results are represented in the sensitivity analyses.
Another limitation is that the values assigned for stage 1
mortality after a two- or three-month wait were based on
scant data. We are unlikely to obtain any more information
in that regard as these strategies are not in current practice.
Future directions. Longer-term outcome data for children
with HLHS are becoming available. The survival curve for
infant transplant recipients with congenital heart disease
continues to decline at the rate of about 1% annually after
the first year (25). For the Fontan procedure, those who
survive the first year after the operation have a mortality
,1% per year (13,30,31). As more information becomes
available about outcomes of the treatment strategies for
HLHS, this decision analysis can be refined. The analysis
can also be used to understand how to optimize quality of
life for patients with HLHS as this information becomes
available.
Conclusions. This comparison of six treatment strategies
for HLHS determined that: 1) staged surgery, and 2)
performing transplantation within one month, and then if
no donor is found performing staged surgery, were the
strategies likely to optimize one-year survival at centers and
for patients with average stage 1 mortality and organ
availability rates. The local probability of organ donation
and of stage 1 mortality influenced which strategy optimized
one-year survival. An individual patient’s predicted mortal-
ity risk and predicted organ availability will also influence
the optimal surgical choice. This decision analysis can help
inform the surgical decision for centers that care for patients
with HLHS to determine the treatment strategy with the
highest expected one-year survival.
Implications. A strength of decision analysis is its identi-
fication of important probabilities, showing where more
information is needed, and where improvements are likely
to have the most impact. Figure 3 identifies the probabilities
that matter most: combined stage 1 mortality, stage 2
mortality to one year, the three-month organ donation rate
and mortality after Tx. Improvements in survival and organ
accrual may result in practice changes at some centers.
This decision analysis can be helpful for centers that offer
both treatment strategies and for those that concentrate on
a single strategy. A center offering both surgical options can
use Figure 4 to determine the best treatment strategy by
determining their stage 1 mortality and organ donation
rates. A center that offers a single surgical option can also
Figure 3. Threshold values of one-way sensitivity analyses, which vary each probability separately, are shown. A threshold value is the value of the
probability at which the optimal strategy changed. Thresholds were obtained in the probabilities (shown along the vertical axis) for stage 1 mortality, stage
2 mortality, organ availability and mortality after transplantation. Therefore, these probabilities are most important to the decision. The optimal strategy
for particular values of each probability is shown by the pattern corresponding to the legend (right). For example, a center with a combined stage
1 mortality of 15% would optimize survival by offering staged surgery, whereas a center with a stage 1 mortality of 30% would optimize survival by
listing the patient for one month before performing stage 1 surgery if no donor is found. No thresholds were found for other probabilities. Black
dots indicate the baseline values in the decision tree. The baseline values all lie in probability ranges that favor listing the patient for one month.
Tx 5 transplantation.
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use Figure 4 to determine the optimal treatment strategy. It
is logical to assume that a center performing staged surgery
exclusively has a very low organ donation rate; therefore, by
Figure 4 the staged surgical strategy gives the highest
likelihood of survival at that center. A center that performs
Tx exclusively usually has a high organ donation rate and/or
a high staged surgical mortality; until those factors are
modified, the Tx strategy will likely optimize survival at that
center.
We recognize that no hospital operates in a vacuum.
Should parents choose a surgical strategy with suboptimal
survival outcomes at a particular center, referral to a different
center may improve the infant’s survival chances. Although
parents may choose to have the surgery at a convenient
center, consideration could be made to refer to a center with
significantly better survival outcomes for the procedure of
choice.
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